BLT - Patent issue settled and new 5 year agreement with BSP

On 14 October 2024, based on the information we had on hand at the time, we advised the market about a breach of contract by Bluestone Pharma GmbH (BSP) and Lactosan GmbH & Co. KG (Lactosan).

Since then, BSP and BLIS Technologies Limited (BLIS) have been progressing communications in relation to the patent applications filed by BSP. BLIS and BSP are pleased to report that these negotiations have concluded, with BSP and BLIS agreeing that the patent applications will be jointly owned. This is a positive step forward for both BLIS, BSP and Lactosan, and provides certainty of access for BLIS and its licensees to this market leading technology developed, and contributed to, by BLIS, BSP and Lactosan. As part of this arrangement, BLIS, BSP and Lactosan have released each other of all claims and causes of action arising from the publication of the patent applications.

BLIS would like to thank both BSP and Lactosan for their willingness to engage positively on this matter and the transparent and ethical manner in which both parties have conducted themselves during the course of the negotiations.

BLIS and BSP are also pleased to announce they have renegotiated a five year extension to their existing supply agreement that was scheduled to expire this month.

Ends

For further information, please contact:

Scott Johnson

CEO

+64 21 488 831

About BLIS Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at www.blis.co.nz.

• Patent issue settled and new 5 year agreement with BSP

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

July 29th Morning Report
General Capital Annual Shareholders Meeting Results
MEE - Receivers and Liquidators appointed to King Honey
2 Cheap Cars Group Updates Performance Outlook for FY26
Spark announces Director changes as part of Board renewal
July 28th Morning Report
KMD Brands announces new Group Chief Financial Officer
Commerce Commission to issue SOI re Viridian application
FBU - Moody's affirms FBU Baa3/stable rating
Contact Energy FY25 Financial Results Presentation